文献速递白血病MDS 与骨髓增殖性肿瘤

唐氏综合征髓系白血病结局改善:儿童肿瘤协作组AAML0431试验报告

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
PubMed 文献 · Blood · 2017-04-07

AAML0431试验纳入204例唐氏综合征髓系白血病(ML-DS)患者,采用4周期诱导和2周期强化疗,第2诱导周期使用大剂量阿糖胞苷(HD-araC)并减少1个含柔红霉素的诱导周期。5年无事件生存(EFS)率89.9%,总生存(OS)率93.0%。诱导I第28天流式检测微小残留病(MRD)可预测结局,MRD阴性者5年无病生存率92.7% vs 阳性者76.2%(log-rank P=.011)。

要点

  • ML-DS患者接受AAML0431方案后5年EFS率89.9%、OS率93.0%。
  • 诱导I第28天MRD阴性者5年无病生存率92.7% vs 阳性者76.2%(log-rank P=.011)。
  • 早期使用HD-araC较既往COG研究改善EFS和OS;累积柔红霉素剂量减少25%未影响结局。

核心结论

  • AAML0431试验中早期使用HD-araC较既往COG研究获得更好的EFS和OS。
  • 累积柔红霉素剂量减少25%未影响结局。
  • MRD被确定为ML-DS患者的新预后因素,可用于未来临床试验的风险分层。

研究设计与样本

  • 儿童肿瘤协作组(COG)AAML0431试验,基于既往COG A2971试验治疗方案修改,含4周期诱导和2周期强化疗。
  • 第2诱导周期使用大剂量阿糖胞苷(HD-araC)替代强化周期,并去除4个含柔红霉素诱导周期中的1个。
  • 纳入204例合格患者,其中146例有MRD检测结果。
  • 试验注册号NCT00369317。

主要发现

  • 204例合格患者5年EFS率为89.9%,5年OS率为93.0%。
  • 17例难治/复发性白血病患者5年OS率为34.3%。
  • 诱导I第28天流式MRD可检测的146例中,MRD阴性者(n=125)5年无病生存率为92.7% vs MRD阳性者(n=21)76.2%(log-rank P=.011)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with myeloid leukemia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant treatment-related morbidity and mortality. ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing may improve outcomes while reducing toxicity. The Children's Oncology Group (COG) AAML0431 trial consisted of 4 cycles of induction and 2 cycles of intensification therapy based on the treatment schema of the previous COG A2971 trial with several modifications. High-dose araC (HD-araC) was used in the second induction cycle instead of the intensification cycle, and 1 of 4 daunorubicin-containing induction cycles was eliminated. For 204 eligible patients, 5-year EFS was 89.9% and overall survival (OS) was 93.0%. The 5-year OS for 17 patients with refractory/relapsed leukemia was 34.3%. We determined the clinical significance of minimal residual disease (MRD) levels as measured by flow cytometry on day 28 of induction I. MRD measurements, available for 146 of the 204 patients, were highly predictive of treatment outcome; 5-year disease-free survival for MRD-negative patients (n = 125) was 92.7% vs 76.2% for MRD-positive patients (n = 21) (log-rank P = .011). Our results indicated that earlier use of HD-araC led to better EFS and OS in AAML0431 than in past COG studies. A 25% reduction in the cumulative daunorubicin dose did not impact outcome. MRD, identified as a new prognostic factor for ML-DS patients, can be used for risk stratification in future clinical trials. This trial was registered at www.clinicaltrials.gov as #NCT00369317.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017. PMID: 28389462. doi:10.1182/blood-2017-01-764324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。